lipocalyx.de Report : Visit Site

Technical data of the lipocalyx.de

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host lipocalyx.de. Currently, hosted in Germany and its service provider is Strato AG .

the related websites

bioscience.co.uk aqa.org.uk biotopics.co.uk yobrew.co.uk menfertility.org dailymail.co.uk chem.qmul.ac.uk journeytoforever.org 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache/2.4.33 (Unix) containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

management technology reagents news contact loading... enabling delivery for genomic medicines delivering mrna, sirna or cas9 into target tissues and cells is a key challenge for genetic medicines. at lipocalyx, we are developing viromers®, one of the most advanced delivery solutions for nucleic acids. homepage lipocalyx 2018-01-24t11:42:52+00:00 lipocalyx enters r&d agreement with biontech halle, jan 24th, 2018. lipocalyx, a leading developer of drug delivery systems for nucleic acids, has entered into a research and development agreement with biontech ag exclusive for certain fields. under the agreement, lipocalyx will apply its viromer® technology for the delivery of certain mrna’s and biontech will assume responsibility for the development of the resulting mrna therapeutics. both parties will cooperate in the clinical development of viromer-based mrna formulations. read more the viromer ® solution viromers are polymers emulating endosomal escape properties of the influenza virus. specifically, they undergo a hydrophobic shift in the endosome, which leads to a highly efficient escape and delivery of the payload into the cytosol. how is this achieved? viromers have a pei backbone, which binds to the dna or rna payload. but in contrast to standard pei, viromers are heavily decorated with alkyl groups which provide a hydrophobic shell. and these groups act synergistically with long-chain fatty acids, which sense the low ph inside endosomes and eventually trigger the escape mechanism. in the experiment below, we followed the cellular uptake and endosomal release of an sirna in hela cells. viromers work across many cell types what you have just seen for hela cells and sirna works across many cell types – from cancer cell lines through various myocytes, hepytocytes, epithelia, stem cells through to neurons or macrophages. more than 120 cell types including many primary ones were reported to us working with viromers in vitro. on a different level, we adopted the viromers to work with all major payloads such as mrna, pdna, rna replicons, cas9 rnp or the smaller sirna or antisense oligos, to name the most important ones. macrophage fibroblasts cardiomyocytes lung epithelia hepatic stem cells c6 glioma cortical neurons viromer ® cell culture reagents lipocalyx develops and manufactures the new generation proprietary synthetic transfection reagents viromer® based on high-tech polymers that combine the best features of chemical transfection and mimick the natural uptake of the influenza virus to enable an outstanding transfer of rnas and dna into various hard-to-transfect cells, including primary cells, stem cells or suspension cells. go to shop see customer data (pdf) viromers translate in vivo the results obtained in the culture dish can be translated to in vivo conditions. viromers have been shown to work in all local applications tested so far. we started from muscle or dermal applications and can demonstrate protein expression or subsequent vaccination results. expression of mrna was also shown for lung, brain, in the peritoneum and even upon local application within the intestine. upon systemic injection, viromers deliver payloads predominantly to spleen followed by the liver. mrna vaccination mrna in rat brain mrna in mouse lung effective for all cargoes viromer leads are optimized for mrna, dna, sirna, aso, rna replicons or cas9 rnp effective in most cells viromers work in all cells doing endocytosis safe only transient changes of cytokines and liver enzymes as key safety parameters for delivery systems intrinsic activity viromers do not require co-factors such as apoe viromer status the viromer platform was independently developed by lipocalyx. starting from the concept of exploiting a viral fusion mechanism for delivery of nucleic acids, we synthesized and screened large combinatorial libraries and developed optimal solutions for payloads such as mrna, pdna or sirna. our expertise in formulation science guided us to developed nanoparticle solutions for modern pharma applications. viromers are ready to use, lyophilized materials widely applicable on many different routes efficient carries for vaccination, immunooncology, enzyme replacement studies and many more applications technology fully synthetic polymers with active endosome escape orthogonal to the standard cationic, pegylated lnp paradigm ip ep2125029 construction and use of transfection enhancer elements us20150275220 carboxyalkylated polyamine derivatives as transfection reagents us20150259678 hydroxyalkylated polyamine derivatives as transfection reagents viromer ® is a registered trademaerk in the eu, switzerland, united states and japan research 3 libraries comprising 20.000 compounds describe chemical space and sar formulation 5 lead viromers – lyophilized product – pilot production application preclinical stage with multiple mrna or sirna experienced team. hands-on approach steffen panzner ceo & founder steffen has a name in this industry for being a constant innovator and drug delivery expert. starting in 1999, he was the main inventor of the viromer® and smarticles® technologies and other delivery solutions for protein depots or small molecule targeting. learn more steffen founded lipocalyx in 2011 for the research and development of the viromer platform. he started his entrepreneurship in 1999 as founder and cso of novosom, the developers of the smarticles delivery technology. smarticles were sold to marina biotech in 2010 and are in multiple clinical trials. steffen holds a ph.d. in cell biology from the humboldt university of berlin and a diploma in biochemistry from the u of halle. he enjoyed doing research at harvard, the bioacademy of athens and the european synchrotron facility in grenoble. christian reinsch head of development & co-founder christian knows the drug delivery field for more than 12 years and is co-inventor of several patents for the smarticles and viromer technology. he has responsibility for our formulation development and core lab activities since 2013. learn more christian started his venture in drug delivery in 2005 at novosom ag. initially working on depot formulations for proteins or peptides he quickly joined the team that developed smarticles, a novel, amphoteric class of liposomes. he was the first to analyze the stunning pk properties of long-circulating amphoter ii liposomes and analyzed their delivery of sirna and aso in vivo. in 2011, christian was one of the founders of lipocalyx (acutally its employee number 1) and helped building the company and the viromer technology from scratch. christian’s main expertise is the development of our in-vivo formulations and process development. christian participated in a research fellowship at the bioacademy of athens and holds a ph.d. in pharmaceutical biotechnology and a diploma in molecular genetics, both from the university of halle. lipocalyx corporate history christian and i started lipocalyx in 2011 as one of the first virtual biotechs in germany. we had a concept on paper and some initial funding from htgf and ibg sachsen-anhalt, so instead of doing hardware investments we teamed up with chiroblock out of wolfen, who also became co-founders and are our chemistry partners. learn more together we laid the foundations of the viromer chemistry, constructed the first library and quickly realized that this could be a success. betatesters confirmed our findings and we did our first product roll-out in jan 2013, 18 months after starting the company. meanwhile back in halle we built our sales force and created a network of distributors now spanning the globe. still, it was the tough times probably any small business goes through when creating and selling an innovation from scratch. it was in summer 2014, when a german startup trusted us with their formulation development. we were thrilled to be back in the therapeutics game and our partner is now using the recipe in clinical trials. good luck! we owe you guys. so why not following up with viromers in vivo? so we did with mrna and it worked on the first try. and on the second again (so it was not an artefact). and in many other people‘s hands. we went for improvements, created our library 3 which gave phenomenal leads not only for mrna, but also for all other major payloads, such as sirna, pdna, rna replicons or cas9 rnp. more data are coming in and as we know from prior experience, this is only the beginning. lipocalyx is now looking forward to bring its technology to the next level, providing gmp grade materials and licenses to our partners. contact us and find out what we can do for you specifically. news 24 01, 2018 lipocalyx 2018-01-24t11:47:22+00:00 lipocalyx enters r&d agreement with biontech halle, jan 24th, 2018. lipocalyx, a leading developer of drug delivery systems for nucleic acids, has entered into a research and development agreement with biontech ag exclusive [...] 17 02, 2017 lipocalyx 2017-05-30t17:22:00+00:00 notice of allowance for viromer ip in the united states today, lipocalyx reports the issuance of a notice of allowance for its application 14/432,361 by the us patent and trademark office and positive examination of a related [...] 4 12, 2016 lipocalyx 2017-05-30t18:39:14+00:00 lipocalyx unveils its viromer one platform lipocalyx, a biotech company based in halle, germany, today lifted the shades on its viromer one platform. the novel compound/device combo allows the straightforward transfer of dna [...] 12 10, 2016 lipocalyx 2017-05-30t18:39:42+00:00 grant of european patent on transfection enhancer elements the epo, europe’s patent agency, today announced the grant of patent ep 2125029 to lipocalyx gmbh. the invention of “construction and use of transfection enhancer elements” introduces [...] let’s get started we’re here to help answer your questions. delivery can be a challenge, our experts can guide you through the nanoparticle landscape. we take great pride in using our expertise for you and look forward to hearing from you. your name your email (required) subject your message i’ve read and accept the privacy policy *. (please check off the box to submit the form) copyright 2012 - 2018 lipocalyx gmbh | all rights reserved | imprint | privacy policy we are using cookies to give you the best experience on our website. you can find out more about which cookies we are using in our privacy policy . accept privacy overview strictly necessary cookies powered by gdpr plugin privacy overview this website uses cookies so that we can provide you with the best user experience possible. cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. you can adjust all of your cookie settings by navigating the tabs on the left hand side. strictly necessary cookies strictly necessary cookie should be enabled at all times so that we can save your preferences for cookie settings. if you disable this cookie, we will not be able to save your preferences. this means that every time you visit this website you will need to enable or disable cookies again. enable all save changes

URL analysis for lipocalyx.de

http://www.lipocalyx.de/author/webadmin-16-g-x
http://www.lipocalyx.de/#viromer
http://www.lipocalyx.de/#contact
http://www.lipocalyx.de/#1d9f4afdfec107f7d
http://www.lipocalyx.de/wp-content/uploads/2017/05/viromer-transfection-factbook.pdf
http://www.lipocalyx.de/notice-of-allowance-for-viromer-ip-in-the-united-states
http://www.lipocalyx.de/#9489ae5d9f936e649
http://www.lipocalyx.de/#a21ee7483c507d0d6
http://www.lipocalyx.de/lipocalyx-enters-rd-agreement-with-biontech
http://www.lipocalyx.de/#9d0032154ad513d82
http://www.lipocalyx.de/
http://www.lipocalyx.de/grant-of-european-patent-on-transfection-enhancer-elements
http://www.lipocalyx.de/#technology
http://www.lipocalyx.de/#news
http://www.lipocalyx.de/lipocalyx-unveils-its-viromer-one-platform

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

% Copyright (c) 2010 by DENIC
% Version: 2.0
%
% Restricted rights.
%
% Terms and Conditions of Use
%
% The data in this record is provided by DENIC for informational purposes only.
% DENIC does not guarantee its accuracy and cannot, under any circumstances,
% be held liable in case the stored information would prove to be wrong,
% incomplete or not accurate in any sense.
%
% All the domain data that is visible in the whois service is protected by law.
% It is not permitted to use it for any purpose other than technical or
% administrative requirements associated with the operation of the Internet.
% It is explicitly forbidden to extract, copy and/or use or re-utilise in any
% form and by any means (electronically or not) the whole or a quantitatively
% or qualitatively substantial part of the contents of the whois database
% without prior and explicit written permission by DENIC.
% It is prohibited, in particular, to use it for transmission of unsolicited
% and/or commercial and/or advertising by phone, fax, e-mail or for any similar
% purposes.
%
% By maintaining the connection you assure that you have a legitimate interest
% in the data and that you will only use it for the stated purposes. You are
% aware that DENIC maintains the right to initiate legal proceedings against
% you in the event of any breach of this assurance and to bar you from using
% its whois service.
%
% The DENIC whois service on port 43 never discloses any information concerning
% the domain holder/administrative contact. Information concerning the domain
% holder/administrative contact can be obtained through use of our web-based
% whois service available at the DENIC website:
% http://www.denic.de/en/domains/whois-service/web-whois.html
%

Domain: lipocalyx.de
Nserver: docks08.rzone.de
Nserver: shades01.rzone.de
Status: connect
Changed: 2011-07-18T12:27:08+02:00

  REGISTRAR DENIC eG

  REFERRER http://www.denic.de/

SERVERS

  SERVER de.whois-servers.net

  ARGS -T dn,ace lipocalyx.de

  PORT 43

  TYPE domain

DOMAIN

  NAME lipocalyx.de

NSERVER

  DOCKS08.RZONE.DE 81.169.146.18

  SHADES01.RZONE.DE 85.214.0.231

  STATUS connect

  CHANGED 2011-07-18

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .